Importantly, systemic delivery of an IGF2-neutralizing antibody failed to improve therapeutic efficacy of rHSVQ in intracranial 005 murine glioma and DB7 BCBM tumors, likely due to the inability of the antibody to penetrate the blood-brain barrier (BBB; Supplementary Figure S3A). This evidence concerns the gene IGF2 and glioma.